BERKELEY HEIGHTS and BRIDGEWATER, NJ, September 9,
2003
TM
The conference call can be accessed as follows:
U.S./Canada: Dial (877) 634-8606, reference code: 2741947.
International: Dial (706) 679-3140, reference code:
2741947.
A replay will be available two hours after the completion of the
conference call and archived through Wednesday, October 10, 2003
for 30 days, accessible as follows:
U.S./Canada: Dial (800) 642-1687, enter 2741947 for
conference ID.
International: Dial (706) 645-9291, enter 2741947 for
conference ID.
The audio webcast can also be accessed via the web at Genta's
Investor Relations website at:
http://www.genta.com/genta/InvestorRelation/events.html
and will be archived for 30 days.
About Genta
Genta Incorporated is a biopharmaceutical company with a
diversified product portfolio that is focused on delivering
innovative products for the treatment of patients with cancer. The
Company's research platform is anchored by two major programs that
center on DNA/RNA-based medicines and small molecules.
Genasense
TM
(oblimersen sodium) is the Company's lead compound from its DNA/RNA
Medicines program and is currently undergoing late-stage, Phase 3
clinical testing. The leading drug in Genta's small molecule
program is Ganite
TM
(gallium nitrate injection), which the Company intends to market
for the treatment of cancer-related hypercalcemia that is resistant
to hydration. For more information about Genta, please visit
our website at:
http://www.genta.com/
.
About Aventis
Aventis is dedicated to treating and preventing disease by
discovering and developing innovative prescription drugs and human
vaccines. In 2002, Aventis generated sales of € 17.6 billion,
invested € 3.1 billion in research and development and employed
approximately 71,000 people in its core business. Aventis corporate
headquarters are in Strasbourg, France. For more information about
Aventis and its programs, please visit:
http://www.aventis.com/
This press release and the conference call and webcast to
follow contain forward-looking statements with respect to business
conducted by Genta Incorporated. By their nature, forward-looking
statements and forecasts involve risks and uncertainties because
they relate to events and depend on circumstances that will occur
in the future. There are a number of factors that could cause
actual results and developments to differ materially. For a
discussion of those risks and uncertainties, please see the
Company's Annual
Report/Form 10-K
for 2002
.
SOURCE: Genta Incorporated and Aventis
